CORDIS - EU research results
CORDIS

Podocyte Adaptation Proliferation and Ageing

Publications

Targeted therapy in patients with PIK3CA-related overgrowth syndrome

Author(s): Quitterie Venot, Thomas Blanc, Smail Hadj Rabia, Laureline Berteloot, Sophia Ladraa, Jean-Paul Duong, Estelle Blanc, Simon C. Johnson, Clément Hoguin, Olivia Boccara, Sabine Sarnacki, Nathalie Boddaert, Stephanie Pannier, Frank Martinez, Sato Magassa, Junna Yamaguchi, Bertrand Knebelmann, Pierre Merville, Nicolas Grenier, Dominique Joly, Valérie Cormier-Daire, Caroline Michot, Christine Bole-Fey
Published in: Nature, Issue 558/7711, 2018, Page(s) 540-546, ISSN 0028-0836
Publisher: Nature Publishing Group
DOI: 10.1038/s41586-018-0217-9

mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases

Author(s): Simon C. Johnson, Frank Martinez, Alessandro Bitto, Brenda Gonzalez, Cagdas Tazaerslan, Camille Cohen, Laure Delaval, José Timsit, Bertrand Knebelmann, Fabiola Terzi, Tarika Mahal, Yizhou Zhu, Philip G. Morgan, Margaret M. Sedensky, Matt Kaeberlein, Christophe Legendre, Yousin Suh, Guillaume Canaud
Published in: Kidney International, Issue 95/2, 2019, Page(s) 455-466, ISSN 0085-2538
Publisher: Blackwell Publishing Inc.
DOI: 10.1016/j.kint.2018.08.038

The costimulatory receptor B7-1 is not induced in injured podocytes

Author(s): Emilie Baye, Morgan Gallazzini, Marianne Delville, Christophe Legendre, Fabiola Terzi, Guillaume Canaud
Published in: Kidney International, Issue 90/5, 2016, Page(s) 1037-1044, ISSN 0085-2538
Publisher: Blackwell Publishing Inc.
DOI: 10.1016/j.kint.2016.06.022

B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS

Author(s): M. Delville, E. Baye, A. Durrbach, V. Audard, T. Kofman, L. Braun, J. Olagne, C. Nguyen, G. Deschenes, B. Moulin, M. Delahousse, G. Kesler-Roussey, S. Beaudreuil, F. Martinez, M. Rabant, P. Grimbert, M. Gallazzini, F. Terzi, C. Legendre, G. Canaud
Published in: Journal of the American Society of Nephrology, Issue 27/8, 2016, Page(s) 2520-2527, ISSN 1046-6673
Publisher: Lippincott Williams & Wilkins Ltd.
DOI: 10.1681/ASN.2015091002

Intellectual Property Rights

BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS - CLOVES SYNDROME)

Application/Publication number: EP 17705872
Date: 2017-02-17
Applicant(s): Université Paris Descartes

BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS - CLOVES SYNDROME)

Application/Publication number: EP 17705872
Date: 2017-02-17
Applicant(s): Université Paris Descartes

BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS - CLOVES SYNDROME)

Application/Publication number: EP 17705872
Date: 2017-02-17
Applicant(s): Université Paris Descartes

BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS - CLOVES SYNDROME)

Application/Publication number: EP 17705872
Date: 2017-02-17
Applicant(s): Université Paris Descartes

Searching for OpenAIRE data...

There was an error trying to search data from OpenAIRE

No results available